Allergy Therapeutics PLC Block Listing Application (0383X)
November 21 2017 - 2:02AM
UK Regulatory
TIDMAGY
RNS Number : 0383X
Allergy Therapeutics PLC
21 November 2017
21 November 2017
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Company")
Block Listing Application
Allergy Therapeutics (AIM:AGY), the fully integrated specialty
pharmaceutical company specialising in allergy vaccines, announces
that an application has been made to the London Stock Exchange for
admission to AIM for a block listing of 10,000,000 ordinary shares
of 0.1p each in the Company ("Ordinary Shares").
The new Ordinary Shares will not be allotted immediately but
rather will be issued and allotted from time to time pursuant to
the exercise of employee options under the Allergy Therapeutics
2013 Long Term Incentive Plan. On exercise, these new Ordinary
Shares will be issued as fully paid and will rank pari passu in all
respects with the existing Ordinary Shares of the Company.
The expected effective date of admission of these securities to
AIM is on or around 24 November 2017.
- ENDS -
For further information, please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Nick Wykeman, Finance Director
Panmure Gordon
+44 (0) 20 7886 2500
Freddy Crossley / Duncan Monteith, Corporate Finance
Tom Salvesen, Corporate Broking
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / Ivar Milligan / Philippa Gardner
allergytherapeutics@consilium-comms.com
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international specialty
pharmaceutical group focussed on the treatment and diagnosis of
allergic disorders, including immunotherapy vaccines that have the
potential to cure disease. The Group sells proprietary and third
party products from its subsidiaries in nine major European
countries and via distribution agreements in an additional ten
countries. Its broad pipeline of products in clinical development
include vaccines for grass, tree and house dust mite, and peanut
allergy vaccine in pre-clinical development. Adjuvant systems to
boost performance of vaccines outside allergy are also in
development.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics
is headquartered in Worthing, UK with more than 11,000m(2) of
state-of-the-art MHRA-approved manufacturing facilities and
laboratories. The Group, which has achieved double digit compound
annual growth since formation, employs c.500 employees and is
listed on the London Stock Exchange (AIM:AGY). For more
information, please see www.allergytherapeutics.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
ALSFBLLLDFFEFBX
(END) Dow Jones Newswires
November 21, 2017 02:02 ET (07:02 GMT)
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Sep 2023 to Sep 2024